Using a Recruiter for Roles Outside of Your Industry

Using a Recruiter for Roles Outside of Your Industry

Author:  Tara Smylie

Ever find yourself staring at a job opening and thinking, “who is the right person to hire for this”? Anyone who’s ever been in a hiring role can relate. Sometimes, you may know the perfect fit right off the bat – but often, you’re left scratching your head. That’s where a recruiter can step in.

How Can a Recruiter Help?

Imagine having access to a network so vast that it’s more of a meta-network, composed of dozens of well-connected individuals and their wide professional webs: that’s what a recruiter brings to the table. A recruiter can tap into their extensive connections to expand your reach far beyond your LinkedIn contacts. Whether you’re in need of someone who’s mastered multiple software platforms or has hands-on lab experience, a recruiter specializing in filling science-based roles will know where to look.

Not to mention, recruiters are pros at assessing your business needs and finding someone who’s the best of both worlds. A recruiter doesn’t just look at the job description; they’ll analyze your company’s culture, goals, and pain points to find a candidate who ticks all the boxes. Plus, they help you figure out what kind of expertise you actually need. Sometimes, you might think you need a jack-of-all-trades, but what you really need is simply a master of one (or two).

The Trickiest Roles to Fill

Now, let’s dive into the kinds of roles that might leave you feeling out of your depth. Picture this: You need a communications professional, but your company specializes in biotech. You have no idea where to start. A recruiter can bridge that gap, finding someone who fits into your company despite their specialty in something else.

Need a medical writer who can also whip up scientific graphics? A recruiter can help you define exactly what you’re looking for and bring in someone who can handle multiple subject areas with ease.

Recruiters are seasoned pros at crossing industry lines and finding interdisciplinary talent. They can help you snag someone who brings a fresh perspective and a unique talent set to your team. It’s like getting the best of both worlds – someone with strong applicable skills who can also adapt to your industry’s specific needs.

Benefits of the Recruiter Route

Working with a recruiter is like having a secret weapon in your hiring arsenal. A recruiter can help you both expand your network and tap into the one you already have, forging connections you didn’t even know existed. They’ll work with you to sketch out your ideal candidate profile, ensuring you’re all on the same page from the get-go.

Sure, you could train someone from within your company to fill the role, but bringing in a well-suited outsider can offer a fresh perspective you might not have considered. A hire with outside experience will bring new ideas, new strategies, and new ways of thinking that can elevate your team to new heights.

The Takeaway

Recruiters aren’t just there to fill vacancies; they’re there to find the perfect match for roles that fall outside your company’s expertise. They’re your go-to for hiring highly specialized positions or interdisciplinary roles, and they’re equipped with the know-how to find someone who fits your organization like a glove.

If you’re looking to fill a role with a highly qualified candidate, Sci.bio’s recruitment services can help. We know that no two clients are the same, so we provide customized recruiting support that adapts to a given client’s structure and needs, and have placed successful candidates with a variety of companies. Please contact us to connect with a recruiter and discuss your needs, and follow us on LinkedIn to stay up to date.

Related Blogs:

Struggling To Fill A Job Vacancy?
The Collapse of Internal Talent Acquisition Functions – Challenges and Solutions
A Researcher, a Communicator, or Something in Between? Knowing Who to Hire for Each Role

References
1. https://www.sci.bio/struggling-to-fill-a-job-vacancy/
2. https://ca.indeed.com/career-advice/career-development/advantages-of-external-recruitment
3. https://www.linkedin.com/advice/0/how-do-you-recruit-difficult-to-fill-positions
Choosing Candidates That Align with Your Long-Term Goals

Choosing Candidates That Align with Your Long-Term Goals

Author:  Tara Smylie

Hiring the right candidates is far from a straightforward process. You’re not just filling a vacancy; you’re making a decision that could shape the future of your organization. While it might seem simple to choose the most qualified applicant, finding someone whose skills and aspirations align with both your short-term needs and your long-term vision is a delicate process.

Aligning Goals and Vision

It’s not necessarily about finding someone who will stay with you for twenty years, though that might be a bonus, but about identifying a candidate whose personal and professional aspirations complement your company’s objectives.

For instance, consider a candidate eager to develop skills in data analytics. If your company is leveraging big data to drive decisions, this individual’s goals align perfectly with your strategic direction. Their desire to grow in this area means they’re likely to be motivated, engaged, and invested in their role – and as long as they stay with you, they’ll be eager to develop these mutually beneficial skills.

Seeking Growth-Oriented Talent

Long-term alignment involves finding candidates who will help your company grow rather than stagnate. This means selecting individuals who understand the necessity of continuous improvement and see the value of improving what may already function “well enough”.

In the rapidly evolving world of life science and biotech, staying ahead of the curve is crucial. Fresh talent can bring new perspectives, and even spot inefficiencies or opportunities for innovation that existing employees might overlook. A candidate who is curious, adaptable, and proactive can be a catalyst for changes you’ve been seeking.

Tailoring Your Selection to Your Company’s Future

When selecting candidates, consider where your company is today and where it will be in the future. For example, if your company is experiencing rapid growth, you’ll need employees who are adaptable and willing to learn new skills. These individuals thrive in dynamic environments, handle multiple responsibilities, and are comfortable with change.

If your company plans to adopt a new strategy or pivot to a different business model, it’s crucial to find candidates who can adapt to different approaches. You need someone skilled in your current processes but open to implementing new strategies. This flexibility can be a significant asset as your company navigates tough transitions.

Aligning Skills with Present and Future Needs

A candidate’s skills must meet your company’s current needs while also aligning with your long-term goals. It’s a balancing act: you want someone who can contribute immediately while also being a good fit for the future.

Let’s say your company is expanding its digital marketing efforts. A candidate with a strong background in traditional marketing might bring valuable insights, but if they lack experience in digital channels, they might struggle to contribute to their fullest potential right away. However, if this candidate is enthusiastic about learning digital marketing and has demonstrated adaptability, they could still be a great long-term fit.

Practical Steps to Ensure Alignment

To identify candidates whose goals align with your long-term vision, consider these steps:

  1. Clearly Define Your Vision: Before you begin hiring, take inventory of your company’s long-term objectives. This helps identify the traits and skills most important in a candidate.
  2. Assess Alignment During Interviews: Ask candidates about their long-term goals and how they see themselves fitting into your company’s future. Look for signs that their aspirations complement your company goals.
  3. Prioritize Growth Potential: Don’t just look for candidates who meet your current needs; consider their potential to grow with your company. Are they adaptable? Do they have a track record of learning new skills? These qualities are crucial for long-term success.
  4. Consider Cultural Fit: Alignment isn’t just about skills and goals; it’s also about how well a candidate fits with your company culture. A good cultural fit enhances collaboration, productivity, and job satisfaction.

A Team to Stand the Test of Time

By focusing on alignment, you can build a team that not only meets today’s challenges but also drives forward your company’s long-term goals.

If you’re looking to fill a role with a highly qualified candidate, Sci.bio’s recruitment services can help. We know that no two clients are the same, so we provide customized recruiting support that adapts to a given client’s structure and needs and have placed successful candidates with a variety of companies. Please contact us to connect with a recruiter and discuss your needs and follow us on LinkedIn to stay up to date.

Related Blogs:

Hiring with Corporate Culture in Mind
Want Good Hires Who Stick Around? Make Their Careers Your Business
Hiring the Right Person

Resources:
5 Qualities of a Good Employee and Candidate and How to Evaluate Them in an Interview
Selection Process: 7 Steps & Best Practices To Hire Top Talent

Q4 2024 Upcoming FDA Decision Dates (PDUFAs)

Q4 2024 Upcoming FDA Decision Dates (PDUFAs)

As we head into a busy holiday season and look towards 2025, it’s important to stay up-to-date on the news in the ever-evolving biotech industry. During a year of transition such as 2024, the remaining FDA approval dates this year have the potential to solidify trends and shape the outlook for the industry in 2025.

Read on for an overview of the FDA’s upcoming decision dates for new drug approvals in the remainder of 2024.

 
DATE COMPANY NAME DRUG NAME USE/THERAPEUTIC AREA
10-04-2024 Biofrontera Ameluz Actinic keratosis (AK)
10-08-2024 Bristol Myers Squibb Neoadjuvant nivolumab (Opdivo) IIA to IIIB non–small cell lung cancer (NSCLC)
10-08-2024 Zealand Pharma Dasiglucagon Hypoglycemia in Congenital Hyperinsulinism
10-11-2024 Pfizer Hympavzi (marstacimab-hncq) Hemophilia A or B without inhibitors
10-15-2024 Intercept Pharmaceuticals Ocaliva (obeticholic acid) Primary biliary cholangitis (PBC)
10-17-2024 Avadel Pharmaceuticals Lumryz (sodium oxybate) Cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.
10-21-2024 Camurus Oclaiz (CAM2029) Acromegaly
10-25-2024 Iterum Therapeutics ORLYNVAH™ (Oral Sulopenem) Uncomplicated Urinary Tract Infections
10-29-2024 Novartis Asciminib (Scemblix) Chronic myeloid leukemia
11-4-2024 Journey Medical Corporation DFD-29 (minocycline hydrochloride) Inflammatory lesions and erythema of rosacea
11-13-2024 PTC Therapeutics Upstaza (eladocagene exuparvovec) Aromatic L–amino Acid Decarboxylase (AADC) deficiency
11-16-2024 Autolus Therapeutics Obecabtagene autoleucel (obe-cel) Relapsed/refractory adult B-cell acute lymphoblastic leukemia (ALL)
11-27-2024 Roche Inavolisib HR+/HER2– PIK3CA+ Breast Cancer
11-28-2024 Applied Therapeutics Inc. Govorestat (AT-007) Galactosemia type 1
11-29-2024 Zymeworks & Jazz Pharmaceuticals Zanidatamab HER2-Positive Metastatic Biliary Tract Cancer
11-29-2024 BridgeBio Pharma Acoramidis Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
11-30-2024 Shorla Oncology SH-201 Leukemia and other cancers.
12-19-2024 Ionis Pharmaceuticals Olezarsen Familial chylomicronemia syndrome
12-20-2024 Lexicon Pharmaceutical Zynquista (sotagliflozin) Type 1 Diabetes and chronic kidney disease
12-26-2024 Rhythm Pharmaceuticals Imcivree (setmelanotide) Bardet-Biedl syndrome or POMC/LEPR deficiency
12-26-2024 Syndax Pharma Revumenib Relapsed or refractory (R/R) KMT2A-rearranged (KMT2Ar) acute leukemia
12-27-2024 Soleno Therapuetics DCCR (Diazoxide Choline) Prader-Willi Syndrome (PWS)
12-28-2024 Checkpoint Therapeutics Cosibelimab Advanced Cutaneous Squamous Cell Carcinoma
12-28-2024 Xcovery Holdings Ensartinib Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)
12-29-2024 Halozyme Therapeutics & Bristol Myers Squibb Opdivo (nivolumab) Advanced or Metastatic Solid Tumors
12-30-2024 Neurocrine Biosciences Crinecerfont Congenital adrenal hyperplasia (CAH)
Dec 2024 BeiGene Tevimbra (tislelizumab) Unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
Q4 2024 AstraZeneca Tagrisso (osimertinib) Stage III EGFR-mutated lung cancer
Q3 2024 Upcoming FDA Decision Dates (PDUFAs)

Q3 2024 Upcoming FDA Decision Dates (PDUFAs)

As we move into the second half of 2024, following a hopeful uptick for the biotech industry in the first two quarters, it’s more important than ever to stay on top of the news in this ever-evolving industry. Some of the most crucial developments to keep up with are the approaching FDA approval dates, which provide insight into the industry’s outlook for the rest of the year.

Read on for a rundown of the FDA’s upcoming decision dates for new drug approvals in the third quarter of 2024.

 
DATE COMPANY NAME DRUG NAME USE/THERAPEUTIC AREA
01/3/2024 Checkpoint Therapeutics Cosibelimab Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
01/5/2024 Novan Berdazimer Gel, 10.3% Molluscum Contagiosum
01/12/2024 Astellas Olbetuximab Gastroesophageal junction (GEJ) adenocarcinoma
01/12/2024 Astellas Pharma Zolbetuximab Gastric Cancer
01/13/2024 GC Biopharma GC5107B Primary Humoral Immunodeficiency (PI)
01/17/2024 Merck WELIREG (belzutifan) Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
01/20/2024 Merck Keytruda (pembrolizumab) Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
01/20/2024 Theratechnologies Tesamorelin F8 Formulation Reduction of excess abdominal fat in adults with HIV who have lipodystrophy
01/23/2024 Heron Therapeutics ZYNRELEF (bupivacaine and meloxicam) Post-Operative Pain
01/24/2024 Liquidia Corporation Yutrepia (treprostinil) Pulmonary Arterial Hypertension (PAH); Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD)
01/26/2024 Defender Pharmaceuticals scopolamine (DPI-386) Motion Sickness
01/31/2024 Sanofi and Regeneron Dupixent (dupilumab) Eosinophilic esophagitis (EoE)
01/31/2024 Vyluma NVK002 Myopia
02/13/2024 Ipsen Onivyde (irinotecan liposome injection) Metastatic pancreatic ductal adenocarcinoma
02/22/2024 Venatorx Pharmaceuticals cefepime-taniborbactam Complicated Urinary Tract Infections (cUTI), including Pyelonephritis
02/24/2024 Iovance Biotherapeutics Lifileucel Advanced Melanoma
02/24/2024 Alvotech AVT02 Inflammatory diseases including rheumatoid arthritis
02/26/2024 Minerva Neurosciences Roluperidone Schizophrenia- Negative Symptoms
03/4/2024 Eyenovia APP13007 Post-operative inflammation and pain following ocular surgery
03/4/2024 Vanda Pharmaceuticals HETLIOZ (tasimelteon) Non-24-Hour Sleep-Wake Disorder (Non-24) in adults
03/8/2024 Viatris and Mapi Pharma Copaxone (Glatiramer Acetate Depot) Relapsed forms of multiple sclerosis (MS)
03/13/2024 Mirum Pharmaceuticals Livmarli (maralixibat) Cholestatic pruritus in patients with progressive familial intrahepatic cholestasis (PFIC)
03/14/2024 Madrigal Pharmaceuticals Resmetirom Nonalcoholic steatohepatitis (NASH)
03/14/2024 Bristol Myers Squibb Breyanzi (lisocabtagene maraleucel) Relapsed/refractory large B-cell lymphoma (LBCL)
03/16/2024 Optinose XHANCE Chronic rhinosinusitis with nasal polyps (CRSwNP)
03/18/2024 Orchard Therapeutics OTL-200 Metachromatic leukodystrophy (MLD)
03/21/2024 Italfarmaco Group Givinostat Duchenne Muscular Dystrophy (DMD)
03/23/2024 Incyte ruxolitinib myelofibrosis, polycythemia vera, and graft vs. host disease (GVHD)
03/26/2024 Merck Sotatercept Pulmonary arterial hypertension (PAH)
03/27/2024 Akebia Therapeutics Vadadustat Anemia in patients with CKD undergoing dialysis
03/27/2024 Esperion NEXLETOL (bempedoic acid) Lowers the level of cholesterol in the blood
03/30/2024 Vertex and CRISPR Therapeutics Casgevy (exagamglogene autotemcel) Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
03/31/2024 Rocket Pharmaceuticals RP-L201 (marnetegragene autotemcel) Leukocyte adhesion deficiency-I (LAD-I)
03/31/2024 Regeneron Pharmaceuticals Odronextamab (REGN1979) Relapsed/refractory follicular lymphoma or relapsed/refractory diffuse large B-cell lymphoma (DLBCL)
04/01/2024 AstraZeneca Voydeya (danicopan) Extravascular hemolysis in adults with paroxysmal nocturnal hemoglobinuria (PNH)
04/02/2024 Vanda Pharmaceuticals Fanapt Manic or mixed episodes associated with bipolar I disorder in adults
04/03/2024 Basilea Pharmaceutica AG ZEVTERA (Ceftobiprole) SAB infections and ABSSSI in adults and for CABP in adults and pediatric patients
04/04/2024 Bristol Myers Squibb & 2seventy Bio Abecma (idecabtagene vicleucel; ide-cel) Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
04/05/2024 Janssen & Legend Biotech Carvykti (ciltacabtagene autoleucel; cilta-cel) Relapsed or refractory multiple myeloma
04/05/2024 Bristol Myers Squibb Opdivo (nivolumab) Unresectable or metastatic urothelial carcinoma
04/05/2024 Supernus Pharmaceuticals SPN-830 Motor fluctuations (OFF episodes) in Parkinson’s disease
04/05/2024 AbbVie/Immunogen ELAHERE Platinum-Resistant Ovarian Cancer
04/23/2024 ImmunityBio N-803 BCG-unresponsive non-muscle invasive bladder carcinoma (NMIBC)
04/28/2024 Aquestive Therapeutics Libervant (diazepam) Buccal Film Seizure clusters in patients between two and five years of age
04/29/2024 PharmaTher KETARX (Ketamine) Mental health, neurological and pain disorders
04/30/2024 Day One Biopharmaceuticals Tovorafenib Relapsed or progressive pediatric low-grade glioma (pLGG)
04/30/2024 X4 Pharmaceuticals Mavorixafor WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome
04/30/2024 Neurocrine Biosciences Inc INGREZZA (valbenazine) Tardive dyskinesia and chorea associated with Huntington’s disease
05/09/2024 Astellas Pharma Inc. PADCEV (enfortumab vedotin-ejfv) Advanced Bladder Cancer
05/09/2024 Merck KEYTRUDA (pembrolizumab) Plus Padcev (enfortumab vedotin-ejfv) Locally advanced or metastatic urothelia
05/09/2024 Pfizer & GENMAB Tivdak Recurrent or Metastatic Cervical Cancer
05/13/2024 Dynavax Technologies Corp HEPLISAV-B Infection caused by all known subtypes of hepatitis B virus
05/14/2024 Ascendis Pharma TransCon PTH (Palopegteriparatide) Hypoparathyroidism
05/23/2024 Bristol Myers Squibb Breyanzi (lisocabtagene maraleucel) Relapsed or refractory follicular lymphoma (FL)
05/25/2024 Abeona Therapeutics Pz-cel Recessive dystrophic epidermolysis bullosa
05/30/2024 Daiichi Sankyo & AstraZeneca Enhertu (trastuzumab deruxtecan) Unresectable or Metastatic HER2 Positive Solid Tumors
05/31/2024 Bristol Myers Squibb Breyanzi (lisocabtagene maraleucel) Relapsed or refractory mantle cell lymphoma (MCL)
06/04/2024 Catalyst Pharmaceutical Firdapse (amifampridine) Lambert-Eaton myasthenic syndrome (“LEMS”)
06/07/2024 GSK AREXVY (RSV Vaccine) Prevention of RSV disease in adults aged 50-59 at increased risk
06/10/2024 Ipsen and GENFIT Elafibranor Rare cholestatic liver disease, primary biliary cholangitis (PBC)
06/12/2024 Amgen Tarlatamab Advanced small cell lung cancer (SCLC)
06/15/2024 Bristol-Myers Squibb Augtyro (repotrectinib) NTRK-Positive Locally Advanced or Metastatic Solid Tumors
06/16/2024 Geron Corporation Imetelstat Lower risk myelodysplastic syndromes (MDS)
06/17/2024 Merck & Ligand Pharmaceuticals V116 Prevent of invasive pneumococcal disease and pneumococcal pneumonia
06/21/2024 Sarepta Therapeutics ELEVIDYS (delandistrogene moxeparvovec-rokl) Duchenne muscular dystrophy (DMD)
06/21/2024 Argenx VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Chronic inflammatory demyelinating polyneuropathy (CIDP)
06/21/2024 Merck & Co Inc. KEYTRUDA (pembrolizumab) Advanced endometrial cancer
06/21/2024 Bristol-Myers Squibb KRAZATI (adagrasib) KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC)
06/21/2024 Harmony Biosciences WAKIX (pitolisant) Excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy
06/26/2024 Merck & Daiichi Sankyo Patritumab deruxtecan (HER3-DXd) Locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more systemic therapies
06/26/2024 Verona Pharma plc Ensifentrine Asthma and chronic obstructive pulmonary disease (COPD)
06/27/2024 Sanofi Dupixent (dupilumab) Chronic obstructive pulmonary disease (COPD) with type 2 inflammation
06/28/2024 AbbVie & GENMAB EPKINLY (Epcoritamab-bysp) Elapsed or Refractory Follicular Lymphoma (FL)
06/30/2024 Rocket Pharmaceuticals RP-L201 (marnetegragene autotemcel) Leukocyte adhesion deficiency-I (LAD-I)
07/7/2024 Arcutis Biotherapeutics Inc. Roflumilast Cream 0.15% Atopic Dermatitis in Adults and Children Down to Age 6
07/15/2024 Orexo AB OX124 opioid overdose
07/19/2024 Phathom Pharmaceuticals Inc VOQUEZNA (vonoprazan) Tablets Heartburn associated with Non-Erosive GERD
07/25/2024 AstraZeneca IMFINZI Resectable non-small cell lung cancer
07/27/2024 Alpha Cognition Inc. ALPHA-1062 Mild-to-moderate Alzheimer’s disease in U.S.
07/31/2024 Xspray Pharma Dasynoc (dasatinib amorphous) Chronic myeloid leukemia (CML)
08/4/2024 Adaptimmune Therapeutics Afami-cel Advanced synovial sarcoma
08/10/2024 Humacyte, Inc. Human Acellular Vessel Vascular trauma
08/13/2024 Citius Pharmaceuticals LYMPHIR (denileukin diftitox) Relapsed or refractory cutaneous T-cell lymphoma (CTCL)
08/14/2024 Ascendis Pharma TransCon PTH (palopegteriparatide) Hypoparathyroidism
08/14/2024 Gilead Sciences Seladelpar Primary Biliary Cholangitis (PBC)
08/20/2024 Royal Pharma vorasidenib IDH-mutant glioma
08/22/2024 Regeneron Pharmaceuticals Linvoseltamab Relapsed/refractory (R/R) multiple myeloma (MM)
08/23/2024 GSK Jemperli (dostarlimab) Primary advanced or recurrent endometrial cancer
08/28/2024 Incyte Corporation / Syndax Pharmaceuticals Axatilimab Chronic Graft-Versus-Host Disease
09/5/2024 Travere Therapeutics / Ligand Pharmaceuticals Filspari (sparsentan) IgA Nephropathy
09/7/2024 AVADEL PHARMACEUTICALS LUMRYZ Cataplexy or EDS in the pediatric narcolepsy population
09/18/2024 VANDA PHARMACEUTICALS Tradipitant Gastroparesis
09/21/2024 Zevra Therapeutics / XOMA Corporation Arimoclomol Niemann-Pick disease type C
09/23/2024 Heron Therapeutics ZYNRELEF Instillation to produce postsurgical analgesia for up to 72 hours after soft tissue and orthopedic procedures
09/24/2024 IntraBio IB1001 (N-acetyl-L-leucine) Niemann-Pick disease Type C (NPC)
09/25/2024 Merck KEYTRUDA (pembrolizumab) Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma
09/26/2024 Syndax Pharmaceuticals Revumenib Relapsed or refractory (R/R) KMT2A-rearranged (KMT2Ar) acute leukemia
09/26/2024 Bristol-Myers Squibb KarXT Schizophrenia in adults
09/27/2024 Regeneron Pharmaceuticals / Sanofi Dupixent Chronic obstructive pulmonary disease (COPD) with type 2 inflammation
09/27/2024 Sanofi Sarclisa (isatuximab-irfc) in combination with bortezomib, lenalidomide, and dexamethasone treatment of transplant-ineligible newly diagnosed multiple myeloma
Q2 2024 Pfizer Fidanacogene elaparvovec Hemophilia B
Q2 2024 BeiGene Beukina (zanubrutinib) Relapsed or refractory follicular lymphoma
Q2 2024 Roche XOLAIR (omalizumab) Asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), chronic spontaneous urticaria (CSU)
Q2 2024 AstraZeneca TAGRISSO (osimertinib) Non-small cell lung cancer (NSCLC)
Q2 2024 AstraZeneca FluMist Quadrivalent Active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine.
Adapting to Changing Candidate Needs in 2024

Adapting to Changing Candidate Needs in 2024

Author:  Tara Smylie

As we approach the summer of 2024, the biotech job market continues to evolve at lightning speed. To attract top talent in an ever-changing hiring landscape, you need to stay ahead of the curve and understand exactly what the candidates of today are looking for. So, how have candidate’s needs and wants changed since 2023?

The Biotech Skills Gap

For several years now, there has been a growing gap in biotech skills – or in other words, a shortage of candidates who are trained to fill the roles many companies are scrambling to fill in 2024. One way to tackle this gap: teaming up with educational institutions training the employee soon to enter the workforce. By working together to develop educational materials and curricula, you can ensure that students are getting the skills they need to succeed in the real world.

Another effective way to bridge the biotech skills gap is by implementing in-house training programs. By investing in the professional development of your existing workforce, you can upskill employees and prepare them for the evolving demands of the biotech industry. In-house training programs can be tailored to the specific needs of your company, ensuring that employees are equipped with the particular skills required to excel in their roles.

What Attracts the Best Employees in 2024?

It’s 2024, and flexibility is key: candidates want the freedom to set their own schedules. Now, that doesn’t mean letting them work whenever they want, but being open to flexible working hours is a huge perk. After all, in a world where employees are often spread across various time zones, a rigid schedule just doesn’t cut it anymore.

At least some leeway around remote work is almost a must for the modern-day workplace. That said, it’s important to keep things personal. Embrace the digital age by conducting Zoom interviews, using online questionnaires, and giving virtual workplace tours. These digital tools not only make the hiring process more efficient, but also help candidates get a feel for your company culture – even if they’re miles away.

Lastly, don’t forget about branding! Working with a recruiter to develop a strong company message can make you more appealing to top candidates. Your employer brand extends beyond just your company website and social media presence, but to every touchpoint candidates have with your organization, from the recruitment process to onboarding and beyond. A strong employer brand can help you attract passive candidates who may not be actively looking for a new job but are drawn to your company’s reputation as an employer of choice.

Workplace Culture

In 2024, a positive workplace culture is not just a nice-to-have; it’s a must-have. Candidates are actively seeking out environments that prioritize collaboration, support, and camaraderie. They want to work in a place where they feel valued and appreciated, where they can contribute to a shared vision and be part of a team that feels like family.

But what exactly does a positive workplace culture look like in 2024? For starters, it means valuing teamwork above all else. Candidates want to work in an environment where everyone is encouraged to share ideas, collaborate on projects, and support one another. Whether it’s brainstorming sessions, cross-functional team projects, or company-wide initiatives, candidates want to feel like they are part of something bigger than themselves.

Additionally, candidates are drawn to companies that know how to have fun. In 2024, employees want to work for a company that knows how to strike the right balance between work and play. Whether it’s hosting team-building activities, organizing company-wide events, or simply celebrating milestones together, candidates want to work for a company that doesn’t shy away from a little fun. After all, a happy team is a productive team!

Making Your Offer Competitive

With so many companies competing for the best employees, it can be tough to stand out. But don’t worry – we’ve got your back! If you’re looking to fill a role with a highly qualified candidate, Sci.bio’s recruitment services can help. We know that no two clients are the same, so we provide customized recruiting support that adapts to a given client’s structure and needs and have placed successful candidates with a variety of companies. Please contact us to connect with a recruiter and discuss your needs, and follow us on LinkedIn to stay up to date.

Related Blogs:
1. Job Perks that Matter Most to Candidates
2. An Offer They Can’t Refuse
3. Struggling To Fill A Job Vacancy?

References
1. The Future of Biotech Talent Acquisition: Trends and Predictions for 2024
2. Top 5 Job Seekers’ Expectations in 2024
3. Best Practices in Recruiting

Q2 2024 Upcoming FDA Decision Dates (PDUFAs)

Q2 2024 Upcoming FDA Decision Dates (PDUFAs)

When you work in an industry as rapidly changing as biotechnology, it’s crucial to stay up to date. Awareness of the FDA’s new drug approval dates is especially crucial: the decisions put forth on these dates can significantly affect the outlook of the companies involved, and these ramifications often reverberate through the industry as a whole.

Read on for a rundown of the FDA’s upcoming decision dates for new drug approvals in the first quarter of 2024.

DATE COMPANY NAME DRUG NAME USE/THERAPEUTIC AREA
04/01/2024 AstraZeneca Voydeya (danicopan) Extravascular hemolysis in adults with paroxysmal nocturnal hemoglobinuria (PNH)
04/02/2024 Vanda Pharmaceuticals Fanapt Manic or mixed episodes associated with bipolar I disorder in adults
04/03/2024 Basilea Pharmaceutica AG ZEVTERA (Ceftobiprole) SAB infections and ABSSSI in adults and for CABP in adults and pediatric patients
04/04/2024 Bristol Myers Squibb & 2seventy Bio Abecma (idecabtagene vicleucel; ide-cel) Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
04/05/2024 Janssen & Legend Biotech Carvykti (ciltacabtagene autoleucel; cilta-cel) Relapsed or refractory multiple myeloma
04/05/2024 Bristol Myers Squibb Opdivo (nivolumab) Unresectable or metastatic urothelial carcinoma
04/05/2024 Supernus Pharmaceuticals SPN-830 Motor fluctuations (OFF episodes) in Parkinson’s disease
04/05/2024 AbbVie/Immunogen ELAHERE Platinum-Resistant Ovarian Cancer
04/23/2024 ImmunityBio N-803 BCG-unresponsive non-muscle invasive bladder carcinoma (NMIBC)
04/28/2024 Aquestive Therapeutics Libervant (diazepam) Buccal Film Seizure clusters in patients between two and five years of age
04/29/2024 PharmaTher KETARX (Ketamine) Mental health, neurological and pain disorders
04/30/2024 Day One Biopharmaceuticals Tovorafenib Relapsed or progressive pediatric low-grade glioma (pLGG)
04/30/2024 X4 Pharmaceuticals Mavorixafor WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome
04/30/2024 Neurocrine Biosciences Inc INGREZZA (valbenazine) Tardive dyskinesia and chorea associated with Huntington’s disease
05/09/2024 Astellas Pharma Inc. PADCEV (enfortumab vedotin-ejfv) Advanced Bladder Cancer
05/09/2024 Merck KEYTRUDA (pembrolizumab) Plus Padcev (enfortumab vedotin-ejfv) Locally advanced or metastatic urothelia
05/09/2024 Pfizer & GENMAB Tivdak Recurrent or Metastatic Cervical Cancer
05/13/2024 Dynavax Technologies Corp HEPLISAV-B Infection caused by all known subtypes of hepatitis B virus
05/14/2024 Ascendis Pharma TransCon PTH (Palopegteriparatide) Hypoparathyroidism
05/23/2024 Bristol Myers Squibb Breyanzi (lisocabtagene maraleucel) Relapsed or refractory follicular lymphoma (FL)
05/25/2024 Abeona Therapeutics Pz-cel Recessive dystrophic epidermolysis bullosa
05/30/2024 Daiichi Sankyo & AstraZeneca Enhertu (trastuzumab deruxtecan) Unresectable or Metastatic HER2 Positive Solid Tumors
05/31/2024 Bristol Myers Squibb Breyanzi (lisocabtagene maraleucel) Relapsed or refractory mantle cell lymphoma (MCL)
06/04/2024 Catalyst Pharmaceutical Firdapse (amifampridine) Lambert-Eaton myasthenic syndrome (“LEMS”)
06/07/2024 GSK AREXVY (RSV Vaccine) Prevention of RSV disease in adults aged 50-59 at increased risk
06/10/2024 Ipsen and GENFIT Elafibranor Rare cholestatic liver disease, primary biliary cholangitis (PBC)
06/12/2024 Amgen Tarlatamab Advanced small cell lung cancer (SCLC)
06/15/2024 Bristol-Myers Squibb Augtyro (repotrectinib) NTRK-Positive Locally Advanced or Metastatic Solid Tumors
06/16/2024 Geron Corporation Imetelstat Lower risk myelodysplastic syndromes (MDS)
06/17/2024 Merck & Ligand Pharmaceuticals V116 Prevent of invasive pneumococcal disease and pneumococcal pneumonia
06/21/2024 Sarepta Therapeutics ELEVIDYS (delandistrogene moxeparvovec-rokl) Duchenne muscular dystrophy (DMD)
06/21/2024 Argenx VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Chronic inflammatory demyelinating polyneuropathy (CIDP)
06/21/2024 Merck & Co Inc. KEYTRUDA (pembrolizumab) Advanced endometrial cancer
06/21/2024 Bristol-Myers Squibb KRAZATI (adagrasib) KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC)
06/21/2024 Harmony Biosciences WAKIX (pitolisant) Excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy
06/26/2024 Merck & Daiichi Sankyo Patritumab deruxtecan (HER3-DXd) Locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more systemic therapies
06/26/2024 Verona Pharma plc Ensifentrine Asthma and chronic obstructive pulmonary disease (COPD)
06/27/2024 Sanofi Dupixent (dupilumab) Chronic obstructive pulmonary disease (COPD) with type 2 inflammation
06/28/2024 AbbVie & GENMAB EPKINLY (Epcoritamab-bysp) Elapsed or Refractory Follicular Lymphoma (FL)
06/30/2024 Rocket Pharmaceuticals RP-L201 (marnetegragene autotemcel) Leukocyte adhesion deficiency-I (LAD-I)
Q2 2024 Pfizer Fidanacogene elaparvovec Hemophilia B